News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and updates on NDA submissions for icotrokinra and rusfertide, as well as progress in clinical trials for PN-881 and IND-enabling studies for PN-477sc and PN-477o -
-
-
-